Determinants of successful AAV-vectored delivery of HIV-1 bNAbs in early life



Summary

Delivering broadly neutralizing antibodies (bNAbs) against HIV-1 via adeno-associated virus (AAV) vectors in early life holds promise for HIV prevention. Success hinges on several factors: vector design (serotype, promoter choice, and transgene codon optimization impact expression), host factors (immune maturity, pre-existing immunity to AAV, and body weight influence transduction), route of administration (intravenous or intramuscular delivery affects biodistribution and persistence), and bNAb characteristics (affinity, breadth, and effector function contribute to neutralization potency). Optimizing these elements is crucial for achieving sustained therapeutic antibody levels and ultimately, effective HIV-1 protection in infants and children.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!